Tri Chemical Laboratories (4369) FY2027 Q1 Earnings Report

Quick View

Executive Summary

In addition to revenue and profit growth, the key point of this earnings release is that non-operating foreign exchange gains and equity-method investment income boosted Ordinary Income and Net Income. Revenue was ¥7.49B (+14.0% YoY), while Operating Income was ¥2.07B (+20.8%), resulting in an Operating Income margin of 27.6%, an improvement of approximately 1.5pt from the previous year. Ordinary Income was ¥2.49B (+51.5%), and Net Income was ¥1.86B (+53.6%), representing profit growth substantially exceeding the increase in Operating Income. This divergence was attributable to a foreign exchange gain of ¥0.14B and equity-method investment income of ¥0.29B, meaning that a portion of the profit growth from the Ordinary Income stage onward was supported by factors outside operating activities.

Factors Affecting Financial Performance

【Revenue】Revenue was ¥7.49B, representing a 14.0% YoY increase. The Company operates as a single-segment business focused on high-purity chemical compounds used in the manufacture of semiconductors and other products, and expanding demand translated directly into higher revenue. Progress against the full-year company forecast of ¥27.0B was 27.7%, slightly exceeding the standard Q1 progress rate of 25%.

【Profitability】Operating Income was ¥2.07B (+20.8%), growing faster than revenue and indicating operating leverage. The gross margin was 37.4% and the SG&A expense ratio was 9.8%, indicating an improving cost structure compared with the previous year. Ordinary Income of ¥2.49B (+51.5%) and Net Income of ¥1.86B (+53.6%) benefited significantly from ¥0.44B in non-operating income, including a ¥0.14B foreign exchange gain and ¥0.29B in equity-method investment income. Consequently, the growth rates of Ordinary Income and Net Income substantially exceeded that of Operating Income. No extraordinary income or loss items were identified. In conclusion, the Company achieved revenue and profit growth.

Segment Analysis

The Group operates as a single segment comprising the business of high-purity chemical compounds used in the manufacture of semiconductors and other products, and does not disclose performance by segment.

Key Financial Indicators

【Profitability】The Operating Income margin of 27.6% improved from approximately 26.1% in the same period of the previous year, while the Net Income margin also increased to 24.8% from approximately 18.4%. The gross margin was 37.4%, reflecting a high-value-added product mix.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥1.78B, or 0.96x Net Income of ¥1.86B, indicating a small divergence between earnings and cash flow. However, OCF as a percentage of estimated EBITDA (¥2.67B) was only 0.66x, suggesting that an increase in working capital restrained cash conversion.【Investment Efficiency】ROE (cumulative quarterly basis) was 5.0%, equivalent to approximately 20% on an annualized basis. Capital expenditures of ¥2.42B were approximately 4.0x depreciation and amortization expense of ¥0.60B, indicating an active investment phase focused on capacity expansion.【Financial Soundness】The Equity Ratio remained high at 77.9%, while interest-bearing debt stood at only ¥5.14B. With current assets of ¥22.70B and current liabilities of ¥4.85B, the Company has substantial short-term payment capacity.

Cash Flow Analysis

OCF was ¥1.78B, a substantial 157.9% increase from the same period of the previous year, converting nearly all of Net Income of ¥1.86B into cash. However, the breakdown shows working capital funding requirements arising from an ¥0.85B increase in inventories, a ¥0.91B decrease in trade payables, and a ¥0.51B increase in trade receivables, resulting in a reduction from OCF before working capital changes of ¥2.56B to actual OCF. Investing Cash Flow was a net outflow of ¥2.43B, of which capital expenditures accounted for ¥2.42B, indicating that the Company is in a growth investment phase. Financing Cash Flow was positive by ¥1.12B; proceeds from long-term borrowings of ¥2.40B contributed positively, while dividend payments of ¥1.09B represented an outflow. As a result, free cash flow was negative ¥0.65B, indicating that capital expenditures during the period could not be fully funded by OCF alone. Nevertheless, cash and deposits remained substantial at ¥7.80B, and the financial foundation represented by an Equity Ratio of 77.9% supports the parallel execution of investments and dividend payments.

Earnings Quality

Of Net Income of ¥1.86B, Operating Income of ¥2.07B generated from recurring business activities is the primary source. However, the growth from the Ordinary Income stage onward includes non-operating factors consisting of a ¥0.14B foreign exchange gain and ¥0.29B in equity-method investment income, both of which may fluctuate depending on the business environment and the performance of affiliated companies. Non-operating income of ¥0.44B was equivalent to approximately 21% of Operating Income and was the primary reason that the growth rate of Ordinary Income (+51.5%) significantly exceeded the growth rate of Operating Income (+20.8%). Accruals—the difference between earnings on an accrual basis and cash earnings—were small, and the fact that OCF reached 0.96x Net Income is positive from an earnings-quality perspective. However, changes in working capital, including increases in inventories and trade receivables and a decrease in trade payables, pressured cash flow. The fact that earnings growth has not translated directly into cash generation requires monitoring.

Earnings Forecast and Guidance

The full-year company forecasts are Revenue of ¥27.0B (+13.1% YoY), Operating Income of ¥6.00B (+1.7%), and Ordinary Income of ¥6.30B (-11.1%), with no revisions to the forecasts during the quarter. Q1 progress rates were 27.7% for Revenue, 34.5% for Operating Income, 39.4% for Ordinary Income, and 40.3% for Net Income, all exceeding the standard progress rate of 25%. The particularly high progress rates for Ordinary Income and Net Income reflect the inclusion of non-operating factors such as foreign exchange gains and equity-method investment income. Together with the full-year Ordinary Income forecast of -11.1% YoY, this suggests that the plan incorporates a decline in non-operating income and normalization of profit margins toward the second half of the fiscal year. The full-year Operating Income margin assumption is 22.2%, below the Q1 result of 27.6%; profitability trends in subsequent quarters will therefore be central to achieving the plan.

Shareholder Returns

The full-year dividend forecast is ¥35.0 per share, with no revision during the quarter. The Payout Ratio based on the full-year EPS forecast of ¥141.55 is approximately 24.7%, below the sustainability benchmark of approximately 60%, indicating ample dividend capacity from an earnings perspective. Share repurchases were ¥0.00B in Q1 and were therefore virtually nonexistent, making dividends the primary form of shareholder returns. OCF of ¥1.78B exceeded the projected annual total dividend amount (approximately ¥1.14B based on the number of shares outstanding). In addition, given cash and deposits of ¥7.80B and the low level of interest-bearing debt, the Company has sufficient financial capacity to execute capital expenditures and dividend payments in parallel.

Risk Factors

1. Business concentration risk: The Company operates as a single-segment business focused on high-purity chemical compounds used in the manufacture of semiconductors and other products. Semiconductor market conditions and customers’ capital expenditure trends therefore directly affect revenue and profit margins.

2. Working capital and inventory risk: Inventories increased from the previous year and became a factor depressing OCF. Combined with a ¥0.91B decrease in trade payables and a ¥0.51B increase in trade receivables, fluctuations in demand could lead to inventory accumulation and increased funding requirements.

3. Dependence on non-operating income: The high growth rates of Ordinary Income and Net Income were supported by a ¥0.14B foreign exchange gain and ¥0.29B in equity-method investment income. These items are susceptible to fluctuations in foreign exchange rates and the performance of affiliated companies and cannot be considered as stable as the growth in Operating Income (+20.8%).

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Return

Growth and Capital Efficiency

※Source: Compiled by the Company

Key Earnings Highlights

1. The Operating Income margin expanded to 27.6%, and Operating Income growth of 20.8%, exceeding Revenue growth of 14.0%, demonstrates the effect of operating leverage through fixed-cost absorption.

2. The substantial growth in Ordinary Income and Net Income includes non-operating factors such as foreign exchange gains and equity-method investment income. These factors must be evaluated separately from earnings power based on Operating Income.

3. Capital expenditures reached approximately 4.0x depreciation and amortization expense, and free cash flow temporarily turned negative. Along with the increase in inventories, the emergence of investment returns and the trend in working capital efficiency will be key areas to monitor.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,229–¥1,303 at ±1% for the cost of equity, and ¥1,262–¥1,270 at ±0.1 for ω.

Notes:

• Because progress of Net Income against the full-year forecast (40%) exceeds the standard level (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of schedule tend to exceed forecasts. For businesses with strong seasonality, the adjustment may be excessive).
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual income model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a strong start, with revenue growth, operating-margin expansion and substantially faster growth in ordinary and net income. Revenue increased 14.0% year on year to ¥7.488bn. Operating income rose 20.8% to ¥2.069bn, exceeding sales growth and demonstrating positive operating leverage. The operating margin improved by approximately 150bp to 27.6% from 26.1% in the prior-year quarter. Gross profit increased to ¥2.800bn and the gross margin was 37.4%, approximately 40bp below the prior-year level. The slight gross-margin compression was more than offset by SG&A discipline, as SG&A declined 5.5% year on year to ¥0.731bn despite the increase in revenue. Consequently, SG&A fell to 9.8% of sales from 11.8% a year earlier. Ordinary income increased 51.5% to ¥2.485bn and net income increased 53.6% to ¥1.855bn. Net margin expanded by approximately 640bp to 24.8% from 18.4%, supported by operational improvement and a favorable non-operating comparison. Foreign exchange moved from a ¥0.336bn loss in the prior-year quarter to a ¥0.142bn gain in FY2027 Q1, a favorable swing that materially aided the acceleration in ordinary income relative to operating income. Equity-method earnings of ¥0.295bn were also a meaningful contributor to non-operating profit. Operating cash flow of ¥1.776bn covered 96% of net income, indicating broadly sound near-term cash realization, although it did not fully match earnings. Free cash flow was negative ¥0.651bn because capital expenditure of ¥2.423bn exceeded operating cash generation. This investment intensity is deliberate growth investment, with CapEx running at 4.01x depreciation, but it also raises execution and cash-conversion requirements. The company funded part of the investment program through a net increase in borrowings, while maintaining a very strong current ratio of 468.0% and low debt-to-equity of 0.28x. Q1 progress versus full-year guidance is ahead of a standard seasonal 25% pace for sales and all profit measures, although the favorable foreign-exchange comparison means the quarterly profit run-rate should not be extrapolated mechanically. The ¥35 full-year DPS forecast implies a 24.7% payout ratio based on forecast EPS of ¥141.55, leaving substantial capacity to retain cash for expansion.

Profitability Analysis

Annualized DuPont ROE is 20.2%, comprising a 24.8% net profit margin, 0.635x asset turnover and 1.28x financial leverage. The principal driver of the high annualized ROE is profitability rather than balance-sheet leverage, since the 1.28x leverage factor is conservative. Operating profitability strengthened: the annualized Q1 operating margin reached 27.6%, up about 150bp year on year, as revenue rose 14.0% while SG&A fell 5.5%. This indicates strong operating leverage and favorable fixed-cost absorption in the high-purity chemical business. Gross margin was 37.4%, down around 40bp year on year, suggesting that the operating-margin gain was driven by overhead leverage rather than improved product gross profitability. Net-margin expansion to 24.8% from 18.4% was larger than the operating-margin increase because non-operating income rose to ¥0.444bn and non-operating expenses declined to ¥0.028bn. In particular, the reversal from a prior-year foreign-exchange loss to a ¥0.142bn FX gain inflated ordinary-income growth to 51.5%, above the 20.8% increase in operating income. Equity-method earnings of ¥0.295bn, equivalent to roughly 14% of operating income, also support profit but are less directly tied to the core manufacturing operation. The effective tax rate was 25.3%, producing a normal tax burden of 0.746. The interest burden of 1.201 reflects net non-operating income rather than financial stress, while interest coverage of 91.56x confirms that interest expense is immaterial. EBITDA was ¥2.674bn and the EBITDA margin was 35.7%, underscoring substantial underlying operating cash-earnings capacity. There is no material intangible-asset burden evident, with intangible assets representing only 0.2% of total assets. Overall, the annualized Q1 profitability profile is excellent, but the non-operating FX tailwind means recurring operating income is the cleaner measure of sustainable earnings momentum.

Growth Assessment

The 14.0% revenue increase to ¥7.488bn points to continued demand growth in the company’s single business of high-purity chemical compounds for semiconductor and related manufacturing. Operating income growth of 20.8% outpaced revenue growth, reflecting favorable operating leverage despite modest gross-margin pressure. The company operates as a single segment, so the core business is the high-purity chemical-compound operation. Full-year guidance calls for revenue of ¥27.0bn, up 13.1% year on year, and operating income of ¥6.0bn, up 1.7%. Q1 revenue represents 27.7% of the full-year forecast, 2.7 percentage points above the standard 25% Q1 progress rate. Q1 operating income represents 34.5% of the annual forecast, 9.5 percentage points above the standard pace. Ordinary income progress is 39.4% and net-income progress is 40.3%, respectively 14.4 and 15.3 percentage points above the standard pace. The above-standard ordinary and net-income progress partly reflects the ¥0.478bn year-on-year FX comparison swing, so it does not necessarily signal an equivalent upgrade to recurring earnings potential. Nevertheless, Q1 operating-income progress is also robust and supports management’s revenue-growth outlook. CapEx of ¥2.423bn, equivalent to 32.4% of Q1 revenue, indicates a major capacity or productivity investment phase. CapEx at 4.01x depreciation supports future production capability but elevates the importance of ramp-up timing, utilization and returns on new assets. Investment securities of ¥6.228bn, or 13.2% of assets, and equity-method earnings also mean investment performance can influence reported profit growth. The lack of a forecast revision at Q1 indicates management has retained its initial assumptions despite the strong opening quarter.

Financial Health

Balance-sheet liquidity is exceptionally strong, with current assets of ¥22.699bn against current liabilities of ¥4.850bn. The current ratio is 468.0% and the quick ratio is 458.6%, both well above conventional liquidity thresholds. Working capital totals ¥17.849bn, providing a substantial buffer for capital spending and normal operating volatility. Cash and deposits are ¥7.798bn, equivalent to 16.5% of total assets. Total equity is ¥36.761bn and the equity ratio is 77.9%, supporting considerable balance-sheet resilience. Interest-bearing debt is ¥5.141bn and debt-to-equity is a conservative 0.28x. Debt-to-capital is 12.3%, debt/EBITDA is 1.92x, and EBITDA interest coverage is 118.32x; these metrics indicate ample debt-servicing capacity. There is no current-ratio or debt-to-equity warning: current assets comfortably cover short-term obligations, and the company is not reliant on aggressive leverage. Long-term loans increased ¥2.058bn, or 66.8% year on year, to ¥5.141bn. Financing cash flow included ¥2.400bn of proceeds from long-term loans, while repayments were only ¥0.160bn, indicating borrowings were used to help fund the elevated investment program. This debt increase remains manageable given the liquidity position and low leverage, but it makes the return and utilization of new production assets more important. Accounts payable decreased ¥0.892bn, or 43.6%, to ¥1.153bn, reducing supplier financing. Inventories declined ¥0.971bn, or 68.1%, to ¥0.456bn on the balance-sheet line, which released cash during the quarter. Property, plant and equipment is ¥17.491bn, representing 37.1% of total assets, confirming a capital-intensive production base. Investment securities total ¥6.228bn, a sizeable 13.2% of assets, and therefore securities valuation and investment-income movements remain relevant to capital quality.

Notable B/S Changes

Inventories: -¥0.971bn (-68.1%) to ¥0.456bn - contributed to a ¥0.854bn operating-cash-flow release during Q1, although annualized DIO remains elevated at 138 days and inventory-cycle efficiency requires monitoring. Long-term loans: +¥2.058bn (+66.8%) to ¥5.141bn - borrowings increased alongside ¥2.423bn of Q1 capex; leverage remains conservative at 0.28x debt-to-equity and 1.92x debt/EBITDA. Accounts payable: -¥0.892bn (-43.6%) to ¥1.153bn - reduced supplier financing and used ¥0.914bn of operating cash flow, increasing reliance on internal cash generation or borrowing during the investment phase.

Cash Flow Quality

Operating cash flow was ¥1.776bn, equal to 0.96x net income of ¥1.855bn. This is below a high-quality threshold of 1.0x but above the 0.8x level generally associated with a material earnings-quality concern. The accruals ratio was only 0.2%, which supports the view that reported earnings are not being driven by excessive accounting accruals. Operating cash flow improved substantially from ¥0.689bn in the prior-year quarter, consistent with the improvement in earnings and working-capital releases. Inventory reduction contributed ¥0.854bn of cash, while the decrease in trade receivables contributed ¥0.507bn. Conversely, the decrease in trade payables used ¥0.914bn of cash, partially reversing the benefit from inventory and receivables. The company generated negative free cash flow of ¥0.651bn because capital expenditure of ¥2.423bn exceeded operating cash flow. The negative FCF is not evidence of weak operating profitability; it reflects an expansionary capital-spending phase, with CapEx at 4.01x depreciation. However, FCF is not currently self-funding for the full investment program and financing inflows were used alongside internal cash generation. Cash conversion, measured as operating cash flow divided by EBITDA, was 0.66x and triggers the LOW_CASH_CONVERSION alert. The root cause is that depreciation-supported EBITDA of ¥2.674bn has not yet translated fully into operating cash flow after taxes, working-capital movements and other operating cash items. In the context of a semiconductor-materials manufacturer undertaking heavy investment, sub-0.7x quarterly cash conversion can occur during capacity expansion, but it remains below the stated 0.9x excellence benchmark. Its impact is that sustained expansion will require disciplined management of working capital, capex phasing and financing despite strong accounting earnings. Annualized inventory days of 138 trigger the HIGH_INVENTORY_DAYS alert. The root cause is a long production and inventory cycle relative to the benchmark of below 60 days, which can reflect safety-stock requirements, specialized inputs and work-in-process inherent in high-purity chemical manufacturing. The impact is greater exposure to demand changes, inventory valuation risk and cash absorption if production or customer qualification schedules are delayed. The annualized cash conversion cycle of 166 days also triggers the LONG_CCC alert. The root cause is the combination of long inventory holding and the broader collection-to-payment cycle, and the impact is that a meaningful share of operating capital remains tied up before being recovered as cash. These working-capital indicators should be monitored even though the quarter’s inventory reduction supported current operating cash flow.

Dividend Sustainability

The full-year dividend forecast is ¥35 per share. Based on forecast EPS of ¥141.55, the implied dividend payout ratio is 24.7%. This payout is well below the 60% sustainability benchmark and leaves substantial earnings retention for capacity expansion, working capital and balance-sheet flexibility. There were no meaningful share repurchases in the quarter, so the dividend payout ratio is the appropriate shareholder-return metric. Annualized Q1 EPS was ¥57.09, and Q1 net income of ¥1.855bn comfortably exceeds the annualized-equivalent quarterly dividend commitment implied by the full-year DPS forecast. Cash dividends paid during the quarter were ¥1.088bn, reflecting the company’s payment schedule and not a direct measure of FY2027 Q1 dividend coverage. Operating cash flow of ¥1.776bn exceeded that cash dividend payment, but free cash flow was negative ¥0.651bn after elevated capex. Accordingly, the dividend appears earnings-supported and balance-sheet-supported, while internally funded dividend-plus-capex coverage depends on future operating cash conversion. Net cash resources, low leverage and high liquidity provide additional capacity to maintain the indicated dividend through the current investment phase. No dividend forecast revision was announced.

Risk Assessment

Business risks include Semiconductor-cycle risk: the single high-purity chemical-compound business is exposed to customer fab utilization, semiconductor capital-spending cycles and qualification timing., Inventory and production-cycle risk: annualized DIO of 138 days and a 166-day cash conversion cycle indicate capital is tied up for an extended period; weaker demand or delayed customer adoption could increase obsolescence and cash-release risk., Capacity-expansion execution risk: CapEx of ¥2.423bn in Q1, 4.01x depreciation, requires timely commissioning, customer qualification and utilization to earn an adequate return., Foreign-exchange risk: FY2027 Q1 included a ¥0.142bn FX gain versus a ¥0.336bn loss a year earlier; this favorable swing contributed materially to ordinary-income growth and may reverse., Chemical-manufacturing risk: operations face potential raw-material availability, quality-control, process-safety, environmental-regulatory and customer-specification risks..

Financial risks include Free-cash-flow risk: FCF was negative ¥0.651bn as capex exceeded operating cash flow, making future expansion partly dependent on cash balances and external funding., Debt increased 66.8% year on year to ¥5.141bn, primarily alongside new borrowing for investment; leverage remains low but should be monitored if investment spending persists., Investment-income and valuation risk: investment securities represent 13.2% of assets, while equity-method earnings of ¥0.295bn contribute to non-operating profit., Supplier-credit reduction: accounts payable fell 43.6% year on year, reducing a source of operating funding and potentially lengthening the cash conversion burden..

Key concerns include Highest priority: the combination of aggressive capex, low cash conversion of 0.66x and a long 166-day annualized cash conversion cycle could constrain self-funded growth if demand or asset ramp-up underperforms., High priority: operating performance is strong, but ordinary and net-income growth were amplified by non-recurring-to-period FX movement; recurring operating income should remain the principal earnings indicator., Moderate priority: annualized DIO of 138 days is above the 90-day warning threshold and warrants monitoring by raw-material, work-in-process and finished-goods stage., Mitigant: liquidity, capital adequacy, interest coverage and leverage metrics are strong, materially reducing near-term refinancing and solvency risk..

Investment Implications

Key takeaways include Revenue grew 14.0% and operating income grew 20.8%, with operating margin improving to 27.6%., Annualized ROE of 20.2% is driven primarily by a very high 24.8% net margin rather than leverage., Q1 sales, operating income, ordinary income and net income are running ahead of standard 25% full-year progress, although FX gains enhanced below-the-line performance., The company is in a pronounced investment phase: CapEx was ¥2.423bn, 4.01x depreciation, producing negative FCF despite solid operating cash flow., The balance sheet remains a major strength, with a 468.0% current ratio, 77.9% equity ratio, 0.28x debt-to-equity and 118.32x EBITDA interest coverage., Working-capital efficiency is the main area requiring scrutiny, given 0.66x cash conversion, 138 annualized inventory days and a 166-day annualized cash conversion cycle., The indicated ¥35 DPS implies a modest 24.7% forecast payout ratio, preserving flexibility during the capacity-investment cycle..

Metrics to watch include Operating margin and gross margin, to determine whether Q1 SG&A leverage is sustainable., FX gains or losses and equity-method earnings, to separate recurring core earnings from non-operating volatility., Operating cash flow/EBITDA, with improvement above the 0.7x warning threshold and toward 0.9x as the key objective., Annualized DIO and annualized cash conversion cycle, particularly the pace of inventory normalization after the Q1 cash release., CapEx, depreciation, borrowing growth and free cash flow, to assess whether new capacity becomes self-funded., Progress against the ¥27.0bn sales and ¥6.0bn operating-income full-year forecasts..

Regarding relative positioning, The company combines exceptionally high annualized profitability and conservative leverage with a capital-intensive expansion profile. Its 27.6% operating margin, 20.2% annualized ROE and very strong liquidity position compare favorably with typical manufacturing benchmarks, while cash conversion and working-capital duration are weaker than desired and are the principal operational counterweights.